INNV trades 55.6% below Wall Street's consensus target of $14.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes INNV achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, InnovAge Holding Corp. (INNV) has a Wall Street consensus price target of $14.00, based on estimates from 9 covering analysts. With the stock currently trading at $9.00, this represents a potential upside of +55.6%. The company has a market capitalization of $1.22B.
Analyst price targets range from a low of $14.00 to a high of $14.00, representing a 0% spread in expectations. The median target of $14.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 2 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, INNV trades at a trailing P/E of -40.9x. Analysts expect EPS to grow +53.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ALHCAlignment Healthcare, Inc. | $1.6B | $7.86 | $19.00 | +141.7% | Buy | 43.3x | 16 |
 OSCROscar Health, Inc. | $7.9B | $30.53 | $34.00 | +11.4% | Hold | 17.7x | 12 |
 ENSGThe Ensign Group, Inc. | $10.2B | $175.46 | $215.00 | +22.5% | Buy | 22.5x | 13 |
 CCRNCross Country Healthcare, Inc. | $428M | $13.25 | $12.09 | -8.8% | Hold | 143.2x | 14 |
 UNHUnitedHealth Group Incorporated | $337.2B | $371.29 | $473.89 | +27.6% | Buy | 18.7x | 52 |
 HUMHumana Inc. | $45.0B | $374.80 | $418.53 | +11.7% | Hold | 40.9x | 44 |
 CVSCVS Health Corp. | $109.6B | $85.86 | $111.20 | +29.5% | Buy | 10.7x | 41 |
 CNCCentene Corp. | $30.7B | $62.07 | $68.29 | +10.0% | Buy | 12.7x | 44 |
 MOHMolina Healthcare, Inc. | $9.9B | $189.37 | $205.45 | +8.5% | Buy | 36.1x | 39 |
 WELLWelltower Inc. | $165.7B | $229.94 | $258.38 | +12.4% | Buy | 81.0x | 35 |
Quick answers to the most common questions about buying INNV stock.
The consensus Wall Street price target for INNV is $14, representing 55.6% upside from the current price of $9. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
INNV has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is leaning bearish, with 2 Sell/Strong Sell ratings. The consensus 12-month price target of $14 implies 55.6% upside from current levels.
INNV's current price is $9 with a consensus target of $14 (55.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $14 for INNV, while the most conservative target is $14. The consensus of $14 represents the median expectation. These targets typically reflect 12-month expectations.
INNV is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 6 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month INNV stock forecast based on 9 Wall Street analysts shows a consensus price target of $14, with estimates ranging from $14 (bear case) to $14 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on INNV, with a "Hold" consensus rating and $14 price target (55.6% upside). 1 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
INNV analyst price targets range from $14 to $14, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $14 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.